Skip to main content
Top
Published in: World Journal of Pediatrics 5/2024

11-05-2024 | Review Article

Current understanding of ELF4 deficiency: a novel inborn error of immunity

Authors: Hong-Qiang Du, Xiao-Dong Zhao

Published in: World Journal of Pediatrics | Issue 5/2024

Login to get access

Abstract

Background

ELF4 deficiency has been recently recognized as a novel disorder within the spectrum of inborn errors of immunity (IEIs), specifically categorized as a “disease of immune dysregulation.” Cases of this condition, reported by our team and others, are very limited worldwide. As such, our current knowledge of this new disease remains preliminary. This review aims to provide a brief overview of the clinical manifestations, pathogenesis, and treatment strategies for this novel IEI.

Data sources

A comprehensive review was conducted after an extensive literature search in the PubMed/Medline database and websites concerning transcriptional factor ELF4 and reports concerning patients with ELF4 deficiency. Our search strategy was “ELF4 OR ETS-related transcription factor Elf-4 OR EL4-like factor 4 OR myeloid Elf-1-like factor” as of the time of manuscript submission.

Results

The current signature manifestations of ELF4 deficiency disorder are recurrent and prolonged oral ulcer, abdominal pain, and diarrhea in pediatric males. In some cases, immunodeficiency and autoimmunity can also be prominent. Targeted Sanger sequencing or whole exome sequencing can be used to detect variation in ELF4 gene. Western blotting for ELF4 expression of the patient’s cells can confirm the pathogenic effect of the variant. To fully confirm the pathogenicity of the variant, further functional test is strongly advised. Glucocorticoid and biologics are the mainstream management of ELF4 deficiency disorder.

Conclusions

Pediatric males presenting with recurring ulcerations in digestive tract epithelium with or without recurrent fever should be suspected of DEX. When atypical presentations are prominent, variations in ELF4 gene should be carefully evaluated functionally due to the complex nature of ELF4 function. Experience of treating DEX includes use of glucocorticoid and biologics and more precise treatment needs more patients to identify and further mechanistic study.

Graphical abstract

Appendix
Available only for authorised users
Literature
1.
2.
go back to reference Dorsey MJ, Condino-Neto A. Improving access to therapy for patients with inborn errors of immunity: a call to action. J Allergy Clin Immunol Pract. 2023;11:1698–702.CrossRefPubMed Dorsey MJ, Condino-Neto A. Improving access to therapy for patients with inborn errors of immunity: a call to action. J Allergy Clin Immunol Pract. 2023;11:1698–702.CrossRefPubMed
3.
go back to reference Ahmed Meelad R, Abd Hamid IJ, Zainudeen ZT, Hashim IF, Azizuddin MNA, Mangantig E, et al. Health-related quality of life of patients and families with primary immunodeficiency in Malaysia: a cross-sectional study. J Clin Immunol. 2023;43:999–1006.CrossRefPubMed Ahmed Meelad R, Abd Hamid IJ, Zainudeen ZT, Hashim IF, Azizuddin MNA, Mangantig E, et al. Health-related quality of life of patients and families with primary immunodeficiency in Malaysia: a cross-sectional study. J Clin Immunol. 2023;43:999–1006.CrossRefPubMed
4.
go back to reference Bruton OC. Agammaglobulinemia. Pediatrics. 1952;9:722–8. Bruton OC. Agammaglobulinemia. Pediatrics. 1952;9:722–8.
5.
go back to reference Tangye SG, Al-Herz W, Bousfiha A, Cunningham-Rundles C, Franco JL, Holland SM, et al. Human inborn errors of immunity: 2022 update on the classification from the International Union of Immunological Societies Expert Committee. J Clin Immunol. 2022;42:1473–507.CrossRefPubMedPubMedCentral Tangye SG, Al-Herz W, Bousfiha A, Cunningham-Rundles C, Franco JL, Holland SM, et al. Human inborn errors of immunity: 2022 update on the classification from the International Union of Immunological Societies Expert Committee. J Clin Immunol. 2022;42:1473–507.CrossRefPubMedPubMedCentral
8.
go back to reference Nigrovic PA, Lee PY, Hoffman HM. Monogenic autoinflammatory disorders: conceptual overview, phenotype, and clinical approach. J Allergy Clin Immunol. 2020;146:925–37.CrossRefPubMedPubMedCentral Nigrovic PA, Lee PY, Hoffman HM. Monogenic autoinflammatory disorders: conceptual overview, phenotype, and clinical approach. J Allergy Clin Immunol. 2020;146:925–37.CrossRefPubMedPubMedCentral
9.
go back to reference Kim ES, Kim D, Yoon Y, Kwon Y, Park S, Kim J, et al. Needs for increased awareness of gastrointestinal manifestations in patients with human inborn errors of immunity. Front Immunol. 2021;12:698721.CrossRefPubMedPubMedCentral Kim ES, Kim D, Yoon Y, Kwon Y, Park S, Kim J, et al. Needs for increased awareness of gastrointestinal manifestations in patients with human inborn errors of immunity. Front Immunol. 2021;12:698721.CrossRefPubMedPubMedCentral
10.
go back to reference Tyler PM, Bucklin ML, Zhao M, Maher TJ, Rice AJ, Ji W, et al. Human autoinflammatory disease reveals ELF4 as a transcriptional regulator of inflammation. Nat Immunol. 2021;22:1118–26.CrossRefPubMedPubMedCentral Tyler PM, Bucklin ML, Zhao M, Maher TJ, Rice AJ, Ji W, et al. Human autoinflammatory disease reveals ELF4 as a transcriptional regulator of inflammation. Nat Immunol. 2021;22:1118–26.CrossRefPubMedPubMedCentral
11.
go back to reference Salinas SA, Mace EM, Conte MI, Park CS, Li Y, Rosario-Sepulveda JI, et al. An ELF4 hypomorphic variant results in NK cell deficiency. JCI Insight. 2022;7:e155481.CrossRefPubMedPubMedCentral Salinas SA, Mace EM, Conte MI, Park CS, Li Y, Rosario-Sepulveda JI, et al. An ELF4 hypomorphic variant results in NK cell deficiency. JCI Insight. 2022;7:e155481.CrossRefPubMedPubMedCentral
12.
go back to reference Sun G, Qiu L, Yu L, An Y, Ding Y, Zhou L, et al. Loss of function mutation in ELF4 causes autoinflammatory and immunodeficiency disease in human. J Clin Immunol. 2022;42:798–810.CrossRefPubMed Sun G, Qiu L, Yu L, An Y, Ding Y, Zhou L, et al. Loss of function mutation in ELF4 causes autoinflammatory and immunodeficiency disease in human. J Clin Immunol. 2022;42:798–810.CrossRefPubMed
13.
go back to reference Sun G, Wu M, Lv Q, Yang X, Wu J, Tang W, et al. A multicenter cohort study of immune dysregulation disorders caused by ELF4 variants in China. J Clin Immunol. 2023;43:933–9.CrossRefPubMed Sun G, Wu M, Lv Q, Yang X, Wu J, Tang W, et al. A multicenter cohort study of immune dysregulation disorders caused by ELF4 variants in China. J Clin Immunol. 2023;43:933–9.CrossRefPubMed
14.
go back to reference Suico MA, Shuto T, Kai H. Roles and regulations of the ETS transcription factor ELF4/MEF. J Mol Cell Biol. 2017;9:168–77.PubMedPubMedCentral Suico MA, Shuto T, Kai H. Roles and regulations of the ETS transcription factor ELF4/MEF. J Mol Cell Biol. 2017;9:168–77.PubMedPubMedCentral
15.
16.
go back to reference Miyazaki Y, Sun X, Uchida H, Zhang J, Nimer S. MEF, a novel transcription factor with an Elf-1 like DNA binding domain but distinct transcriptional activating properties. Oncogene. 1996;13:1721–9.PubMed Miyazaki Y, Sun X, Uchida H, Zhang J, Nimer S. MEF, a novel transcription factor with an Elf-1 like DNA binding domain but distinct transcriptional activating properties. Oncogene. 1996;13:1721–9.PubMed
17.
go back to reference Aryee DN, Petermann R, Kos K, Henn T, Haas OA, Kovar H. Cloning of a novel human ELF-1-related ETS transcription factor, ELFR, its characterization and chromosomal assignment relative to ELF-1. Gene. 1998;210:71–8.CrossRefPubMed Aryee DN, Petermann R, Kos K, Henn T, Haas OA, Kovar H. Cloning of a novel human ELF-1-related ETS transcription factor, ELFR, its characterization and chromosomal assignment relative to ELF-1. Gene. 1998;210:71–8.CrossRefPubMed
18.
go back to reference Bagger FO, Sasivarevic D, Sohi SH, Laursen LG, Pundhir S, Sonderby CK, et al. BloodSpot: a database of gene expression profiles and transcriptional programs for healthy and malignant haematopoiesis. Nucleic Acids Res. 2016;44:D917–24.CrossRefPubMed Bagger FO, Sasivarevic D, Sohi SH, Laursen LG, Pundhir S, Sonderby CK, et al. BloodSpot: a database of gene expression profiles and transcriptional programs for healthy and malignant haematopoiesis. Nucleic Acids Res. 2016;44:D917–24.CrossRefPubMed
19.
go back to reference Mamonkin M, Puppi M, Lacorazza HD. Transcription factor ELF4 promotes development and function of memory CD8(+) T cells in Listeria monocytogenes infection. Eur J Immunol. 2014;44:715–27.CrossRefPubMed Mamonkin M, Puppi M, Lacorazza HD. Transcription factor ELF4 promotes development and function of memory CD8(+) T cells in Listeria monocytogenes infection. Eur J Immunol. 2014;44:715–27.CrossRefPubMed
20.
go back to reference Suico MA, Yoshida H, Seki Y, Uchikawa T, Lu Z, Shuto T, et al. Myeloid Elf-1-like factor, an ETS transcription factor, up-regulates lysozyme transcription in epithelial cells through interaction with promyelocytic leukemia protein. J Biol Chem. 2004;279:19091–8.CrossRefPubMed Suico MA, Yoshida H, Seki Y, Uchikawa T, Lu Z, Shuto T, et al. Myeloid Elf-1-like factor, an ETS transcription factor, up-regulates lysozyme transcription in epithelial cells through interaction with promyelocytic leukemia protein. J Biol Chem. 2004;279:19091–8.CrossRefPubMed
21.
go back to reference Lu Z, Kim KA, Suico MA, Shuto T, Li JD, Kai H. MEF up-regulates human beta-defensin 2 expression in epithelial cells. FEBS Lett. 2004;561:117–21.CrossRefPubMed Lu Z, Kim KA, Suico MA, Shuto T, Li JD, Kai H. MEF up-regulates human beta-defensin 2 expression in epithelial cells. FEBS Lett. 2004;561:117–21.CrossRefPubMed
22.
go back to reference Hedvat CV, Yao J, Sokolic RA, Nimer SD. Myeloid ELF1-like factor is a potent activator of interleukin-8 expression in hematopoietic cells. J Biol Chem. 2004;279:6395–400.CrossRefPubMed Hedvat CV, Yao J, Sokolic RA, Nimer SD. Myeloid ELF1-like factor is a potent activator of interleukin-8 expression in hematopoietic cells. J Biol Chem. 2004;279:6395–400.CrossRefPubMed
23.
go back to reference Lacorazza HD, Miyazaki Y, Di Cristofano A, Deblasio A, Hedvat C, Zhang J, et al. The ETS protein MEF plays a critical role in perforin gene expression and the development of natural killer and NK-T cells. Immunity. 2002;17:437–49.CrossRefPubMed Lacorazza HD, Miyazaki Y, Di Cristofano A, Deblasio A, Hedvat C, Zhang J, et al. The ETS protein MEF plays a critical role in perforin gene expression and the development of natural killer and NK-T cells. Immunity. 2002;17:437–49.CrossRefPubMed
24.
go back to reference Yamada T, Park CS, Mamonkin M, Lacorazza HD. Transcription factor ELF4 controls the proliferation and homing of CD8+ T cells via the Kruppel-like factors KLF4 and KLF2. Nat Immunol. 2009;10:618–26.CrossRefPubMedPubMedCentral Yamada T, Park CS, Mamonkin M, Lacorazza HD. Transcription factor ELF4 controls the proliferation and homing of CD8+ T cells via the Kruppel-like factors KLF4 and KLF2. Nat Immunol. 2009;10:618–26.CrossRefPubMedPubMedCentral
25.
go back to reference Lee PH, Puppi M, Schluns KS, Yu-Lee LY, Dong C, Lacorazza HD. The transcription factor E74-like factor 4 suppresses differentiation of proliferating CD4+ T cells to the Th17 lineage. J Immunol. 2014;192:178–88.CrossRefPubMed Lee PH, Puppi M, Schluns KS, Yu-Lee LY, Dong C, Lacorazza HD. The transcription factor E74-like factor 4 suppresses differentiation of proliferating CD4+ T cells to the Th17 lineage. J Immunol. 2014;192:178–88.CrossRefPubMed
26.
go back to reference Stewart DM, Tian L, Notarangelo LD, Nelson DL. X-linked hypogammaglobulinemia and isolated growth hormone deficiency: an update. Immunol Res. 2008;40:262–70.CrossRefPubMed Stewart DM, Tian L, Notarangelo LD, Nelson DL. X-linked hypogammaglobulinemia and isolated growth hormone deficiency: an update. Immunol Res. 2008;40:262–70.CrossRefPubMed
27.
go back to reference You F, Wang P, Yang L, Yang G, Zhao YO, Qian F, et al. ELF4 is critical for induction of type I interferon and the host antiviral response. Nat Immunol. 2013;14:1237–46.CrossRefPubMedPubMedCentral You F, Wang P, Yang L, Yang G, Zhao YO, Qian F, et al. ELF4 is critical for induction of type I interferon and the host antiviral response. Nat Immunol. 2013;14:1237–46.CrossRefPubMedPubMedCentral
28.
go back to reference Wang D, Zhang Z, Cui S, Zhao Y, Craft S, Fikrig E, et al. ELF4 facilitates innate host defenses against Plasmodium by activating transcription of Pf4 and Ppbp. J Biol Chem. 2019;294:7787–96.CrossRefPubMedPubMedCentral Wang D, Zhang Z, Cui S, Zhao Y, Craft S, Fikrig E, et al. ELF4 facilitates innate host defenses against Plasmodium by activating transcription of Pf4 and Ppbp. J Biol Chem. 2019;294:7787–96.CrossRefPubMedPubMedCentral
29.
go back to reference Kim YJ, Kim BG, Lee SJ, Lee HK, Lee SH, Ryoo HM, et al. The suppressive effect of myeloid Elf-1-like factor (MEF) in osteogenic differentiation. J Cell Physiol. 2007;211:253–60.CrossRefPubMed Kim YJ, Kim BG, Lee SJ, Lee HK, Lee SH, Ryoo HM, et al. The suppressive effect of myeloid Elf-1-like factor (MEF) in osteogenic differentiation. J Cell Physiol. 2007;211:253–60.CrossRefPubMed
30.
go back to reference Berendsen AD, Olsen BR. Osteoblast-adipocyte lineage plasticity in tissue development, maintenance and pathology. Cell Mol Life Sci. 2014;71:493–7.CrossRefPubMed Berendsen AD, Olsen BR. Osteoblast-adipocyte lineage plasticity in tissue development, maintenance and pathology. Cell Mol Life Sci. 2014;71:493–7.CrossRefPubMed
31.
go back to reference Zhuang H, Zhang X, Zhu C, Tang X, Yu F, Shang GW, et al. Molecular mechanisms of PPAR-gamma Governing MSC osteogenic and adipogenic differentiation. Curr Stem Cell Res Ther. 2016;11:255–64.CrossRefPubMed Zhuang H, Zhang X, Zhu C, Tang X, Yu F, Shang GW, et al. Molecular mechanisms of PPAR-gamma Governing MSC osteogenic and adipogenic differentiation. Curr Stem Cell Res Ther. 2016;11:255–64.CrossRefPubMed
32.
go back to reference Miyazaki Y, Boccuni P, Mao S, Zhang J, Erdjument-Bromage H, Tempst P, et al. Cyclin A-dependent phosphorylation of the ETS-related protein, MEF, restricts its activity to the G1 phase of the cell cycle. J Biol Chem. 2001;276:40528–36.CrossRefPubMed Miyazaki Y, Boccuni P, Mao S, Zhang J, Erdjument-Bromage H, Tempst P, et al. Cyclin A-dependent phosphorylation of the ETS-related protein, MEF, restricts its activity to the G1 phase of the cell cycle. J Biol Chem. 2001;276:40528–36.CrossRefPubMed
33.
go back to reference Mao S, Frank RC, Zhang J, Miyazaki Y, Nimer SD. Functional and physical interactions between AML1 proteins and an ETS protein, MEF: implications for the pathogenesis of t(8;21)-positive leukemias. Mol Cell Biol. 1999;19:3635–44.CrossRefPubMedPubMedCentral Mao S, Frank RC, Zhang J, Miyazaki Y, Nimer SD. Functional and physical interactions between AML1 proteins and an ETS protein, MEF: implications for the pathogenesis of t(8;21)-positive leukemias. Mol Cell Biol. 1999;19:3635–44.CrossRefPubMedPubMedCentral
34.
go back to reference Du H, Xia H, Liu T, Li Y, Liu J, Xie B, et al. Suppression of ELF4 in ulcerative colitis predisposes host to colorectal cancer. iScience. 2021;24:102169. Du H, Xia H, Liu T, Li Y, Liu J, Xie B, et al. Suppression of ELF4 in ulcerative colitis predisposes host to colorectal cancer. iScience. 2021;24:102169.
35.
go back to reference Chen X, Chen J, Feng W, Huang W, Wang G, Sun M, et al. FGF19-mediated ELF4 overexpression promotes colorectal cancer metastasis through transactivating FGFR4 and SRC. Theranostics. 2023;13:1401–18.CrossRefPubMedPubMedCentral Chen X, Chen J, Feng W, Huang W, Wang G, Sun M, et al. FGF19-mediated ELF4 overexpression promotes colorectal cancer metastasis through transactivating FGFR4 and SRC. Theranostics. 2023;13:1401–18.CrossRefPubMedPubMedCentral
36.
go back to reference Liu T, Yu H, Zhang Z, Xie Y, Yang L, You F. Intestinal ELF4 deletion exacerbates alcoholic liver disease by disrupting gut homeostasis. Int J Mol Sci. 2022;23:4825.CrossRefPubMedPubMedCentral Liu T, Yu H, Zhang Z, Xie Y, Yang L, You F. Intestinal ELF4 deletion exacerbates alcoholic liver disease by disrupting gut homeostasis. Int J Mol Sci. 2022;23:4825.CrossRefPubMedPubMedCentral
37.
go back to reference Cao M, Chen P, Peng B, Cheng Y, Xie J, Hou Z, et al. The transcription factor ELF4 alleviates inflammatory bowel disease by activating IL1RN transcription, suppressing inflammatory TH17 cell activity, and inducing macrophage M2 polarization. Front Immunol. 2023;14:1270411.CrossRefPubMedPubMedCentral Cao M, Chen P, Peng B, Cheng Y, Xie J, Hou Z, et al. The transcription factor ELF4 alleviates inflammatory bowel disease by activating IL1RN transcription, suppressing inflammatory TH17 cell activity, and inducing macrophage M2 polarization. Front Immunol. 2023;14:1270411.CrossRefPubMedPubMedCentral
Metadata
Title
Current understanding of ELF4 deficiency: a novel inborn error of immunity
Authors
Hong-Qiang Du
Xiao-Dong Zhao
Publication date
11-05-2024
Publisher
Springer Nature Singapore
Published in
World Journal of Pediatrics / Issue 5/2024
Print ISSN: 1708-8569
Electronic ISSN: 1867-0687
DOI
https://doi.org/10.1007/s12519-024-00807-0

Other articles of this Issue 5/2024

World Journal of Pediatrics 5/2024 Go to the issue